Inspiremd and namsa to partner on cguardians ii pivotal clinical trial of the cguard prime™ 80 cm carotid stent system for use in tcar procedures

Toledo, ohio and miami, feb. 13, 2025 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ prime carotid stent system for the prevention of stroke related to carotid stenosis, and namsa, a world-leading medtech contract research organization (cro) offering global end-to-end development services, today announced that, pursuant to a previously announced strategic outsourcing partnership, the companies are working together to conduct the cguardians ii pivotal study of inspiremd's cguard prime™ 80 cm carotid stent system for use in transcarotid artery revascularization (tcar) procedures.
NSPR Ratings Summary
NSPR Quant Ranking